

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3881228

| | |
|---|---|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| NEW NITRO FORMULATIONS LTD | 12/29/2011 |
| RECEIVING PARTY DATA | |
| Name: | NORTHERN INNOVATIONS AND FORMULATIONS CORP. |
| Street Address: | 381 NORTH SERVICE ROAD W |
| City: | OAKVILLE, ONTARIO |
| State/Country: | CANADA |
| Postal Code: | L6M0H4 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Patent Number: | 5817329 |
| CORRESPONDENCE DATA | |
| Fax Number: | (212)425-5288 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 212-425-7200 |
| Email: | jhardy@kenyon.com |
| Correspondent Name: | KENYON & KENYON LLP |
| Address Line 1: | ONE BROADWAY |
| Address Line 4: | NEW YORK, NEW YORK 10004 |
| ATTORNEY DOCKET NUMBER: | 11411/1702 |
| NAME OF SUBMITTER: | MICHAEL GLYNN |
| SIGNATURE: | /Michael Glynn/ |
| DATE SIGNED: | 05/19/2016 |
| Total Attachments: 2 | |
| source=2011-12-29 - REDACTED - 5,817,329 Assignment (NewNitro to Northern Innovations and Formulations)#page1.tif | |
| source=2011-12-29 - REDACTED - 5,817,329 Assignment (NewNitro to Northern Innovations and Formulations)#page2.tif | |

PATENT ASSIGNMENT AGREEMENT

BETWEEN, New Nitro Formulations Ltd., an Ontario corporation, having a principal place of business at 381 North Service Rd W, Oakville, Ontario Canada L6M 0H4 (hereinafter "Assignor") and **Northern Innovations and Formulations Corp.** an Ontario corporation, having a principal place of business at 381 North Service Rd W, Oakville, Ontario Canada L6M 0H4, (hereinafter "Assignee"):

WHEREAS, the Assignor is the owner of all right, title and interest in and to each and all of the patents and related intellectual property listed in Exhibit A (hereto reproduced and attached) of the Agreement of Purchase and Sale (the "APS") dated December 29, 2011, between the Assignor and the Assignee" (collectively the "Patent");

WHEREAS, the Assignee wishes to acquire from the Assignor all right, title and interest in and to the Patent in accordance with the terms and conditions of the APS;

NOW, THEREFORE, to all whom it may concern, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor by these presents does hereby sell, transfer, convey and assign unto the Assignee its entire right, title and interest in and to the Patent in accordance with the terms and conditions of the APS, and the right to sue for and recover for the past infringement thereof.

NEW NITRO FORMULATIONS LTD.

By: _____



Name: Norm Vanderee

Title: Chief Financial Officer

Date:

EXHIBIT A

ASSETS

Patent Portfolio and other Intellectual Property Rights

1. Patent Portfolio:

- 1.1. US 5,817,329 Acetabolan - Acetyl-L-carnitine;
- 1.2. CAN 2,246,014 Creatine and ALA;
- 1.3. CAN 2,208,047 Creatine and Glycogen;
- 1.4. EPO 798971 Creatine and Glycogen;
- 1.5. EPO 1221865 Nitric Oxide Inducer and Protein;
- 1.6. MEX 244212 Nitric Oxide Inducer and Protein;
- 1.7. MEX 201323 Creatine and Glycogen;
- 1.8. Any other patents, patent applications and patent disclosures, made under or otherwise owned by New Nitro Formulations Ltd. or its predecessors.

2. Other Intellectual Property:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

3. Any and all other rights to existing and future, registrations and applications for any of the foregoing and all other proprietary rights in, or relating to, any of the foregoing, including goodwill associated therewith, remedies against and rights to sue for past infringements, and rights to damages and profits due or accrued in or relating to any of the foregoing.